An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced that CEO Vicente Anido, Jr., Ph.D., will participate in two upcoming virtual investor conferences. The events include the Citi 16th Annual BioPharma Conference on September 9, 2021, at 8:50 a.m. ET, focusing on next-generation retinal therapeutics, and the Wells Fargo Healthcare Conference on September 10, 2021, at 8:40 a.m. ET, featuring a fireside chat. Live webcasts of these discussions will be available on Aerie's website, with replays accessible for 10 business days.
Positive
None.
Negative
None.
DURHAM, N.C.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will participate in the following virtual investor conferences.
Citi 16th Annual BioPharma Conference
Date: Thursday, September 9, 2021
Time: 8:50 a.m. Eastern Time
Panel Discussion: Eyes on the Prize – Next Generation Retinal Therapeutics
Wells Fargo Healthcare Conference
Date: Friday, September 10, 2021
Time: 8:40 a.m. Eastern Time
Presentation Type: Fireside
The panel and fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.
What is Aerie Pharmaceuticals' participation in the Citi 16th Annual BioPharma Conference?
Aerie Pharmaceuticals will participate in the Citi 16th Annual BioPharma Conference on September 9, 2021, at 8:50 a.m. ET.
When is Aerie Pharmaceuticals' presentation at the Wells Fargo Healthcare Conference?
Aerie Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 10, 2021, at 8:40 a.m. ET.
Who is the CEO of Aerie Pharmaceuticals?
Vicente Anido, Jr., Ph.D., is the CEO of Aerie Pharmaceuticals.
How can I access the webcasts for Aerie Pharmaceuticals' conferences?
The webcasts for Aerie Pharmaceuticals' conferences can be accessed on their website, with replays available for 10 business days.
What products does Aerie Pharmaceuticals offer?
Aerie Pharmaceuticals offers Rhopressa® and Rocklatan®, both for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
